 |
|
Moxalactam Plus Ticarcillin or Tobramycin for Treatment of Febrile Episodes in Neutropenic Cancer Patients
Victor Fainstein, MD;
Gerald P. Bodey, MD;
Ricardo Bolivar, MD;
Linda Elting, RN, MPH;
Kenneth B. McCredie, MD;
Michael J. Keating, MD
Arch Intern Med. 1984;144(9):1766-1770.
Abstract
• Moxalactam disodium In combination with ticarcillin disodium or tobramycin sulfate was used to treat 445 episodes of suspected or confirmed infection In patients with cancer. The majority had leukemia and neutropenla. The rate of cures during the 231 confirmed infections was 65% for moxalactam and ticarcillin and 64% for moxalactam and tobramycin. Both regimens were comparable agalpst aerobic gram-negative and polymicrobial Infections. In gram-positive infections, the response rate for moxalactam and ticarcillin was 73% and for moxalactam and tobramycin, 53%. Only three of nine enterococcal Infections responded to treatment. Thirteen percent of all organisms recovered were resistant to moxalactam. Side effects occurred infrequently; the most important was coagulopathy due to moxalactam. Nephrotoxic effects occurred in six patients receiving moxalactam and tobramycin and in none of those receiving moxalactam and ticarcillin. In 39 patients, a superinfection was confirmed. Fourteen were fungal, three were due to enterococcus, and one due to Klebsiella species. Eleven of the 14 fungal episodes occurred in the moxalactamticarcillin group. Moxalactam with ticarcillin and moxalactam with tobramycin are equally active for the Initial treatment of presumed infection In patients with neutropenia.
(Arch Intern Med 1984;144:1766-1770)
Author Affiliations
From the Section of Infectious Diseases, Division of Medicine, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston.
Footnotes
Accepted for publication Feb 20, 1984.
Reprint requests to Section of Infectious Diseases (Box 47), Division of Medicine, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Ave, Houston, TX 77030 (Dr Fainstein).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Comparison of Imipenem to Ceftazidime With or Without Amikacin as Empiric Therapy in Febrile Neutropenic Patients
Rolston et al.
Arch Intern Med 1992;152:283-291.
ABSTRACT
Beta-Lactam Antibiotic Therapy in Febrile Granulocytopenic Patients: A Randomized Trial Comparing Cefoperazone plus Piperacillin, Ceftazidime plus Piperacillin, and Imipenem Alone
Winston et al.
ANN INTERN MED 1991;115:849-859.
ABSTRACT
The Medical Course of Cancer Patients With Fever and Neutropenia: Clinical Identification of a Low-Risk Subgroup at Presentation
Talcott et al.
Arch Intern Med 1988;148:2561-2568.
ABSTRACT
Synergy: Should It Determine Antibiotic Selection in Neutropenic Patients?
Bodey
Arch Intern Med 1985;145:1964-1966.
ABSTRACT
A Multicenter Comparative Trial of Tobramycin and Ticarcillin vs Moxalactam and Ticarcillin in Febrile Neutropenic Patients
Feld et al.
Arch Intern Med 1985;145:1083-1088.
ABSTRACT
Antibiotics in Patients With Neutropenia
Bodey
Arch Intern Med 1984;144:1845-1851.
ABSTRACT
|
